ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1878

Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index

Boyang Zheng1, Mianbo Wang2 and Murray Baron3, 1Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, 2Lady Davis Institute for Medical Research, Montreal, QC, Canada, 3Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: immunosuppressants, Outcome measures, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on skin or organ specific outcomes such as lung involvement. However, a new composite response index in dcSSc (CRISS) was proposed to improve assessment of treatment interventions1. Our aim is to examine the effect of current immunosuppressive therapy on the CRISS in an observational dcSSc cohort.

Methods:

Adult dcSSc patients without prior immunosuppression followed in the Canadian Scleroderma Research Group (CSRG) registry between 2005 and 2017 were included. Patients newly treated with methotrexate, azathioprine, mycophenolate and/or cyclophosphamide for ≥2 years were the exposed group and untreated patients with at least the same follow up duration were controls. To account for disparity between treated and untreated patients, inverse probability of treatment weighting (IPTW) was performed to balance potential confounders: age, sex, disease duration and CRISS variables (modified Rodnan skin score, forced vital capacity, patient and physician global assessments, and HAQ-DI). Overall disease evolution after 1 year was qualified using CRISS which defines improvement as a score ≥0.6. Missing data were multiply imputed and logistic regression was used to obtain pooled odds ratios and confidence intervals.

Results:

301 dcSSc patients were analyzed. Of these, 47 (15.7%) were treated and 254 (84.4%) were untreated. At baseline, treated compared to untreated patients were younger (50.1±10.4 vs. 55.1±12.3 years respectively, p=0.008), had significantly shorter disease duration (5.5±7.4 vs. 11.7±9.3 years respectively, p<0.001) and higher mean physician global assessment scores (4.2±2.3 vs. 2.5±1.9 points respectively, p<0.001). IPTW used to correct for the different treatment probabilities and confounders showed excellent balance between the two groups. Prior to IPTW, treated patients trended towards more improvement after 1 year. However, after IPTW correction, treated patients were significantly more likely than untreated patients to have improved disease, regardless of age, sex, or disease duration (Table 1).

Conclusion:

Assessing the effects of treatment in an observational cohort is intrinsically biased as treated patients will likely have more severe disease.  After balancing using IPTW to reduce these confounders, we demonstrated that patients on immunosuppression are more likely to experience substantial improvement than untreated patients after 1 year using the CRISS score, a newly proposed global measure of disease severity.

1. Khanna D, Berrocal VJ, Giannini EH, et al. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 2016;68(2):299-311.

 

Table 1: Odds of having improved disease after 1 year before and after IPTW adjusted for patient variables

 

Before IPTW

After IPTW

 

OR (95% CI)

p

OR (95% CI)

p

Treatment exposure

2.00 (0.82, 4.92)

0.129

1.85 (1.11, 3.09)

0.018

Female

1.07 (0.41, 2.79)

0.896

1.50 (0.73, 3.05)

0.268

Age

1.00 (0.97, 1.04)

0.861

1.03 (1.00, 1.05)

0.038

Disease duration

1.01 (0.96, 1.05)

0.802

1.00 (0.97, 1.02)

0.809

 


Disclosure: B. Zheng, None; M. Wang, None; M. Baron, None.

To cite this abstract in AMA style:

Zheng B, Wang M, Baron M. Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/immunosuppression-in-diffuse-systemic-sclerosis-improves-outcomes-using-a-novel-composite-response-index/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunosuppression-in-diffuse-systemic-sclerosis-improves-outcomes-using-a-novel-composite-response-index/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology